Malondialdehyde and Nitrous Oxide as Salivary Biomarkers for Different Oral Lesions

Beni-Suef University

Status: Completed

Conditions: Oral Keratoses; Leukoplakia; Oral Lichen Planus; Oral Cancer

Treatments: Diagnostic Test: salivary biomarker

Study type: Observational

Funder types: Other

Identifiers

NCT04267419

FDBSUREC/17022019/AM

Details and patient eligibility

About

investigating the level of malondialdehyde (MDA) & nitric oxide (NO) in saliva in oral premalignant and malignant lesions in order to determine their diagnostic value for the malignant and potentially malignant lesions.

Full description

Being a detrimental disease, cancer development is a very complicated process that requires many sequential steps and depends on a various number of genetic alterations and factors(1). Among these factors are the free radicals which are derived either from endogenous or exogenous sources (5). Free radicals result in an oxidative stress of the affected cells generating a body imbalance between oxidants and antioxidants (6).

In this regard, saliva has been currently used to assess this possible oxidative imbalance through various salivary biomarkers including nitric oxide (NO) and malondialdehyde (MDA). Saliva could be used as a very interesting rich medium, known for its role in diagnosis, prognosis and treatment that has become more prominent in oral diseases (6).

Nitric oxide (NO) is an intercellular messenger molecule having many important biological functions. The levels of nitric oxide in salivary secretions could be used to monitor the severity of many underlying disease processes. Moreover, malondialdehyde (MDA) has been the most frequently used biomarker of oxidative stress in many pathological conditions such as cancer. It resulted from reactive oxygen species lipid degradation and induced toxic stress in affected cells, making both biomarkers a point of focus in monitoring clinical progress of suspected lesions

Enrollment: 100 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• healthy individuals with one of the following oral lesions :

  • keratosis
  • Oral lichen planus
  • oral squamous cell carcinoma
  • oral leukoplakia

Exclusion criteria

• subjects having systemic disorders
• pregnant or lactating females;
• subjects who suffered from any other mucosal lesions;
• severe periodontal inflammation.

Trial design

100 participants in 5 patient groups

healthy Control

Description:

MDA and NO in saliva

Treatment:

Diagnostic Test: salivary biomarker

keratosis

Description:

MDA and NO in saliva

Treatment:

Diagnostic Test: salivary biomarker

leukoplakia

Description:

MDA and NO in saliva

Treatment:

Diagnostic Test: salivary biomarker

Oral lichen Planus

Description:

MDA and NO in saliva

Treatment:

Diagnostic Test: salivary biomarker

oral Squamous cell carcinoma

Description:

MDA and NO in saliva

Treatment:

Diagnostic Test: salivary biomarker